Incyte (INCY) Stock Forecast & Price Target

INCY Forecast - Frequently Asked Questions

What is Incyte's forecast for 2025?

According to the research reports of 18 Wall Street equities research analysts, the average twelve-month stock price forecast for Incyte is $82.53, with a high forecast of $107.00 and a low forecast of $60.00.

Should I buy or sell Incyte stock right now?

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Incyte in the last year. There is currently 1 sell rating, 10 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" INCY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in INCY, but not buy additional shares or sell existing shares.

Does Incyte's stock price have much downside?

According to analysts, Incyte's stock has a predicted downside of -0.73% based on their 12-month stock forecasts.

Has Incyte been upgraded by Wall Street analysts recently?

Over the previous 90 days, Incyte's stock had 1 upgrade by analysts.

What analysts cover Incyte?

Incyte has been rated by research analysts at Bank of America, Barclays, BMO Capital Markets, Citigroup, JPMorgan Chase & Co., Royal Bank Of Canada, Truist Financial, UBS Group, and Wells Fargo & Company in the past 90 days.

Do Wall Street analysts like Incyte more than its competitors?

Analysts like Incyte less than other "medical" companies. The consensus rating for Incyte is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how INCY compares to other companies.